Statistics
The Psyence Biomedical Ltd. stock price is currently $ 3.15 with a total market cap valuation of $ 59,910 (19,019 shares outstanding). The Psyence Biomedical Ltd. is trading on NASDAQ under the ticker sign PBM. Psyence Biomedical Ltd. price is up
Description
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Company Profile
- Full Name: Psyence Biomedical Ltd.
- Sector: Healthcare
- Website: https://www.psyencebiomed.com
